The Cost of Daylight Savings Time

Dr. Jonathan Moustakis

Co-founder and CTO of Lume Health

4 min read

Peptides for Wellness & Health Optimization

Peptides are short chains of amino acids (the same fundamental building blocks that make up proteins) but they function in the body in a unique and highly targeted way. Rather than acting as structural components like many larger proteins, peptides typically serve as biological signaling molecules, helping cells communicate and coordinate complex physiological processes.

They play essential roles in regulating metabolism, hormone release, immune responses, inflammation, tissue repair, appetite, sleep, and many other functions. Examples of naturally occurring peptides include insulin, glucagon, growth hormone–releasing peptides, and numerous immune signaling molecules.

Because of their size and structure, peptides occupy a distinct space between traditional small-molecule drugs and larger biologic therapies. This gives them several unique characteristics:

High specificity

Peptides often bind very precisely to receptors, allowing them to influence particular biological pathways with relatively targeted effects.

Powerful physiological impact

Even small changes in peptide signaling can lead to meaningful changes in metabolism, recovery, or hormonal rhythms.

Shorter biological half-lives

Many peptides are rapidly broken down in the body, which can reduce long-term accumulation but may require careful dosing strategies.

Growing therapeutic interest

Advances in biotechnology have made it easier to design and synthesize peptides, leading to increasing exploration of their potential uses in medicine and longevity science.

For these reasons, peptides are often discussed as a category of their own. They represent a class of bioactive molecules that can directly influence regulatory systems within the body.

However, this biological potency also means that peptides are not risk-free.

Peptides are not risk-free. Before considering their use, it is essential to carefully weigh potential benefits against possible risks: side effects, unknown long-term outcomes, dosing challenges, and product purity. Decisions should be based on credible evidence and ideally made in consultation with a qualified healthcare professional.

The table below summarizes commonly discussed peptides, their mechanisms of action, and the current state of evidence.

A Multiple large RCTs
B Strong RCT; optimization off-label
C Small or surrogate-endpoint human trials
D Limited human evidence
E No persuasive human evidence; primarily preclinical
Regulatory note: WADA status reflects the 2026 Prohibited List. For educational purposes only. Always consult a licensed physician.

Incretin & Metabolic Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
SemaglutideWegovy, Ozempic, RybelsusAObesity (BMI ≥30 or ≥27 + comorbidity); T2DM; CV risk reductionFDA-approved 2021 (obesity). EMA Jan 2022. Rx only.WADA: Not prohibited
TirzepatideZepbound, MounjaroAObesity; T2DM; obstructive sleep apnea in adults with obesityFDA-approved 2022 (T2DM), 2023 (obesity), 2024 (OSA). Rx only.WADA: Not prohibited
LiraglutideSaxenda, VictozaAObesity (BMI ≥30 or ≥27 + comorbidity); T2DMFDA-approved (Rx). Saxenda label current 2025.WADA: Not prohibited
ExenatideByetta, Bydureon ERBT2DM (not primarily indicated for obesity/wellness)FDA-approved (Rx). Byetta label current 2025.WADA: Not prohibited
PramlintideSymlinBT2DM and T1DM insulin adjunct; studied for obesity as lifestyle adjunctFDA-approved (Rx) for diabetes adjunct. Obesity use off-label.WADA: Not prohibited

Growth Hormone (GH) Axis Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
TesamorelinEgrifta WRBHIV lipodystrophy (excess abdominal fat). NOT indicated for weight loss managementFDA-approved (Rx) for HIV lipodystrophy ONLY.WADA: Prohibited (S2)
SermorelinGeref (discontinued)CHistorically: pediatric GH deficiency. Now compounded off-label for anti-aging / body compositionUS product withdrawn. Compounded only. Not FDA-approved.WADA: Prohibited (S2)
CJC-1295CJC-1295 w/ DAC; MOD GRF 1-29CInvestigational: GH/IGF-1 axis enhancement, body composition, anti-agingNot FDA-approved. Higher-risk bulk substance for compounding.WADA: Prohibited (S2)
IpamorelinIpamorelinCInvestigational: GH secretagogue. Phase II RCT for postoperative ileus showed NO significant benefitNot FDA-approved. Bulk substance with potential significant safety risk.WADA: Prohibited (S2)
GHRP-2Pralmorelin (Japan: diagnostic)CClinical GH stimulation/diagnostic use (Japan approved). Wellness use not clinically validatedNot FDA-approved. Japan approval for diagnostic use only.WADA: Prohibited (S2)
GHRP-6GHRP-6DInvestigational: GH secretagogue. No robust wellness outcomes RCT baseNot FDA-approved. FDA compounding risk flagged.WADA: Prohibited (S2)

Melanocortin Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
AfamelanotideScenesse, Melanotan IBErythropoietic protoporphyria (EPP). NOT a tanning drugFDA-approved for EPP indication only (2019).WADA: Not prohibited
Melanotan IIMT-IIEMarketed for tanning/libido. NOT approved anywhere. Serious adverse event case reportsNot FDA-approved. FDA flags significant safety concerns.WADA: Not prohibited
PT-141 (Bremelanotide)VyleesiAHSDD in premenopausal women. NOT for postmenopausal women, men, or performance enhancementFDA-approved June 2019 (NDA 210557). Premenopausal HSDD only.WADA: Not prohibited

Neurobehavioral Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
OxytocinPitocin, intranasal (off-label)CFDA-approved: obstetric indications. Off-label/research: autism social outcomes, anxiety, bondingFDA-approved for obstetric indications only. Intranasal wellness is off-label/research.WADA: Not prohibited
DesmopressinNocdurna, DDAVPBNocturia; central diabetes insipidus; nocturnal enuresis. NOT a wellness agentFDA-approved (Rx). Boxed warning for hyponatremia.WADA: Not prohibited
DSIPEmideltide, Delta Sleep-Inducing PeptideDInvestigational: sleep induction, insomnia. Evidence weak and limitedNot FDA-approved. Higher-risk compounding bulk substance.WADA: Not prohibited
SelankSelankCAnxiety, cognitive enhancement (Russia/Ukraine approved). Research compound in Western marketsApproved in Russia. NOT approved in US, EU, or UK.WADA: Not prohibited
SemaxSemaxDCognitive enhancement, neuroprotection (Russia/Ukraine approved). Not approved in Western marketsApproved in Russia. NOT approved in US, EU, or UK.WADA: Not prohibited

Endocrine Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
Kisspeptin-10Kp-10CInvestigational: reproductive endocrinology, LH/FSH stimulation, emerging sexual function researchNot FDA-approved. FDA compounding risk flagged.WADA: Not prohibited

Repair & Regenerative Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
BPC-157Body Protection Compound-157, PL-14736EInvestigational: GI mucosal healing, tendon/ligament repair, wound healing. Human evidence sparseNot FDA-approved. Bulk substance with potential significant safety risks.WADA: Not prohibited
TB-500TB-500 (LKKTETQ fragment)EInvestigational: tissue repair, wound healing. NOT full-length Thymosin β4Not FDA-approved. Bulk substance with potential significant safety risks.WADA: Not prohibited
LL-37LL-37, Human cathelicidinCInvestigational: wound healing (venous leg ulcers), innate immune modulationNot FDA-approved. FDA compounding risk flagged.WADA: Not prohibited

Immune, Longevity & Other Peptides

Peptide (Brand Names)EvidenceIndicationRegulatory Status
Thymosin Alpha-1Zadaxin, ThymalfasinCHepatitis B/C, cancer adjunct, immune deficiency (approved China, Italy, 35+ countries). Not FDA-approvedApproved in China, Italy (Zadaxin), 35+ countries. NOT FDA-approved.WADA: Not prohibited
GHK-CuCopper tripeptide, copper peptideDCosmetic/dermatologic: skin aging, wound healing (topical). Injectable claims NOT validatedNot FDA-approved as a drug. FDA compounding risk flagged for injectable forms.WADA: Not prohibited
EpithalonEpitalon, Epithalone, AEDGEInvestigational: longevity, circadian rhythm restoration, telomere biology. No robust human clinical evidenceNot approved anywhere. Research use only. FDA compounding risk flagged.WADA: Not prohibited
MOTS-cMOTS-cEInvestigational: metabolic disease, aging, exercise performance. No human RCTsNot approved. Research compound. FDA compounding risk flagged.WADA: Not prohibited
Morning Light, Healthier Life: Why Permanent Standard Time Benefits Our Circadian Clock

Every spring, Americans adjust their clocks forward to daylight saving time, and every fall back to standard time, but these shifts are more than just an inconvenience. The shift each March has been linked to spikes in heart attacks and traffic accidents in the days that follow. Now, new research suggests the health impacts of clock-changing go well beyond those acute effects. In this piece we will look at how a single time policy year-round could make millions of Americans healthier, reducing prevalence of obesity and stroke across the nation.

Why Light Timing Matters for Your Circadian Clock

Humans evolved with a natural circadian rhythm of about 24 hours, synchronized to the solar day-night cycle. Light is the main signal that entrains this internal clock each day. Morning light sends a powerful cue to advance or “speed up” the circadian cycle, helping your central clock stay aligned with local time. Evening light, by contrast, tends to delay or “slow down” the clock. In simple terms, we generally need more light early in the day and less light at night to remain well-synchronized to a 24-hour schedule. If your light exposure is shifted (for example, you miss morning sunlight or get too much bright light late at night), your internal clock can drift out of sync with the world. An out-of-sync circadian rhythm has been linked to a host of health issues, from poor sleep and mood changes to metabolic and cardiovascular problems.

Standard Time vs. Daylight Time: A Healthy Clock for the Body

Given the importance of light timing, the question arises: what happens when we shift the clock itself? In the U.S., we currently switch clocks twice a year. Come March, daylight saving time (DST) jumps sunrise an hour later; in November, standard time (ST) returns sunrise to an earlier hour. This seesaw means months of altered light schedules, and experts have long suspected it’s not ideal for our biology. Leading medical organizations such as the American Medical Association and the American Academy of Sleep Medicine have even called for ending the seasonal time changes, advocating for permanent standard time to maximize morning light. Until now, however, solid data backing one policy over another had been limited.

That changed with a new Stanford-led study by Lara Weed, published in Proceedings of the National Academy of Sciences in 2025. The researchers used mathematical models to compare three scenarios: our current biannual switching (BAS), permanent DST, and permanent ST. They simulated how each policy would influence people’s light exposure throughout the year (based on local sunrise and sunset times) and, in turn, how much circadian disruption or “burden” that would create. The verdict was striking: our habit of switching back and forth is the worst option for circadian health. In contrast, keeping one fixed time year-round leads to significantly less circadian burden, and standard time came out as the healthiest option overall.

“We found that staying in standard time or staying in daylight saving time is definitely better than switching twice a year,” notes Dr. Zeitzer, “with permanent standard time benefiting the most people.” This means aligning our clocks with natural solar time, as standard time does, provides the most robust circadian stability for the majority of people.

Geography and Chronotype: One Size Doesn’t Fit All

Interestingly, the benefits of one time policy over another aren’t uniform across everyone. The study showed that where you live and your chronotype (morning lark versus night owl) influence how much you’d gain from permanent standard time. Geography matters because the United States spans multiple time zones and a wide range of latitudes. People living on the western edge of a time zone currently have considerably later sunrises by the clock (for example, it stays dark later in the morning). These regions suffer more from the lack of morning light, especially under extended daylight saving time, and thus stand to benefit the most from a switch to permanent standard time’s earlier sunrises. In fact, the models predicted greater health improvements for residents in western parts of each time zone under permanent ST compared to those farther east.

Chronotype differences add another twist. If you’re a night owl (an evening person who naturally stays up late and sleeps in later), you tend to have a slightly longer-than-24-hour internal cycle. This makes it harder for you to catch enough morning light under daylight saving time schedules, leaving you more burdened. Owls, who make up a large segment of the population, would therefore see major circadian gains from permanent standard time’s extra morning light. Morning larks, on the other hand, are the minority (about 15 percent of people) with naturally shorter circadian cycles. These early birds often wake up before the rest and feel sleepy sooner in the evening. Counterintuitively, the study found that extreme larks might experience slightly less circadian disruption under permanent DST, since the added evening light helps stretch their short internal day a bit longer. However, for the vast majority of individuals who are not extreme larks, year-round standard time provided the lowest circadian “burden” (the easiest alignment) compared to DST or switching. In summary, permanent ST appears to be the most universally beneficial, while permanent DST might only be preferable for a small slice of very early risers.

A Nationwide Health Impact: Millions Fewer Obesity and Stroke Cases

How do these circadian advantages translate into real health outcomes? To answer that, Weed’s team linked their circadian disruption models to U.S. health data for chronic conditions that have known circadian influences. They focused on two big ones: obesity (metabolic health) and stroke (cardiovascular health), among other conditions. The differences were eye-opening. Under a permanent standard time scenario, the nationwide prevalence of obesity was predicted to drop by about 0.78 percentage points, and stroke prevalence by about 0.09 percentage points, relative to the current switching system. Those percentage changes sound small, but across a country as large as the U.S. they are huge in absolute numbers. A 0.78 percent reduction in obesity equates to roughly 2.6 million fewer Americans classified as obese, and 0.09 percent fewer strokes means about 300,000 fewer stroke cases. In public health terms, that’s a massive improvement potentially preventing numerous deaths and diseases.

Importantly, the study found no significant differences between time policies for illnesses unrelated to circadian rhythms (for example, rates of arthritis did not change). This detail bolsters the case that the observed obesity and stroke improvements are indeed tied to circadian health, not some unrelated factor. While the study didn’t explicitly model other outcomes like mental health, accident rates, or overall mortality, it’s plausible that keeping a steady, sun-aligned schedule year-round would have positive effects there too, given what we know from other research.


Takeaway

This new research provides compelling evidence that how we set our clocks can profoundly influence public health. Of course, adopting permanent standard time won’t magically solve every health problem. People will still need healthy habits and good sleep routines. But as the study by Weed demonstrates, a seemingly small policy choice can have a surprisingly large impact when scaled to a nation of 330 million people. On the order of millions fewer cases of disease, the circadian science is telling us that aligning our social clock with our biological clock matters. As policymakers debate the future of daylight saving time, the message from this research is clear: prioritizing morning sunshine and a stable schedule is a data-backed strategy for a healthier society.

 

  1. References:
    Weed L, Zeitzer JM. Circadian-informed modeling predicts regional variation in obesity and stroke outcomes under different permanent US time policies. Proc Natl Acad Sci U S A. 2025;122(38):e2508293122. doi:10.1073/pnas.2508293122


Dr. Jonathan Moustakis

Co-founder and CTO of Lume Health